European Medicines Agency validates for review Marketing Authorization Application for somatrogon to treat paediatric patients with growth hormone deficiency

Submission for this long-acting recombinant human growth hormone intended for once weekly administration is supported by results of phase 3 trial which met primary endpoint of non-inferiority vs. once daily somatropin injection, as measured by annual height velocity at 12 months

Source:

Biospace Inc.